ARMP
Armata Pharmaceuticals, Inc.
Biotechnology
Market Cap$304M
5Y Perf.+123.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ARMP vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1690.08T
5Y Perf.-59.3%
ARMP vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ARMP | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $304M | $1690.08T |
| Revenue (TTM) | $5M | $0.00 |
| Net Income (TTM) | $-174M | $-168M |
| Gross Margin | 68.8% | — |
| Operating Margin | -6.4% | — |
| Total Debt | $288M | $22M |
| Cash & Equiv. | $9M | $194M |
ARMP vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ARMP
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | 100 | 223.1 | +123.1% |
| DBV Technologies S.… (DBVT) | 100 | 40.7 | -59.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARMP vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARMP leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
ARMP
Armata Pharmaceuticals, Inc.
The Income Pick
ARMP carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.24
- Rev growth -5.2%, EPS growth -8.2%, 3Y rev CAGR -3.8%
- Lower volatility, beta 1.24, current ratio 1.19x
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Long-Run Compounder
DBVT is the clearest fit if your priority is long-term compounding.
- -87.1% 10Y total return vs ARMP's -97.6%
- 0.3% margin vs ARMP's -35.4%
- -89.0% ROA vs ARMP's -207.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARMP | -5.2% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs ARMP's -35.4% |
| Stability / Safety | ARMP | Beta 1.24 vs DBVT's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ARMP | +5.1% vs DBVT's +100.5% |
| Efficiency (ROA) | DBVT | -89.0% ROA vs ARMP's -207.9% |
ARMP vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARMPLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
ARMPArmata Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
ARMP1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DBVT3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
ARMP5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ARMP and DBVT operate at a comparable scale, with $5M and $0 in trailing revenue.
| Metric | ARMPArmata Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $5M | $0 |
| EBITDAEarnings before interest/tax | -$30M | -$112M |
| Net IncomeAfter-tax profit | -$174M | -$168M |
| Free Cash FlowCash after capex | -$26M | -$151M |
| Gross MarginGross profit ÷ Revenue | +68.8% | — |
| Operating MarginEBIT ÷ Revenue | -6.4% | — |
| Net MarginNet income ÷ Revenue | -35.4% | — |
| FCF MarginFCF ÷ Revenue | -5.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -12.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -79.0% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ARMP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ARMPArmata Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $304M | $1690.08T |
| Enterprise ValueMkt cap + debt − cash | $583M | $1690.08T |
| Trailing P/EPrice ÷ TTM EPS | -1.73x | -0.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 62.00x | — |
| Price / BookPrice ÷ Book value/share | — | 0.65x |
| Price / FCFMarket cap ÷ FCF | — | — |
ARMP leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
DBVT leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
| Metric | ARMPArmata Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | — | -130.2% |
| ROA (TTM)Return on assets | -2.1% | -89.0% |
| ROICReturn on invested capital | -36.0% | — |
| ROCEReturn on capital employed | -58.8% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $279M | -$172M |
| Cash & Equiv.Liquid assets | $9M | $194M |
| Total DebtShort + long-term debt | $288M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -1.88x | -189.82x |
DBVT leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
ARMP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARMP five years ago would be worth $20,244 today (with dividends reinvested), compared to $3,172 for DBVT. Over the past 12 months, ARMP leads with a +510.3% total return vs DBVT's +100.5%. The 3-year compound annual growth rate (CAGR) favors ARMP at 83.7% vs DBVT's 5.7% — a key indicator of consistent wealth creation.
| Metric | ARMPArmata Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +26.5% | +3.6% |
| 1-Year ReturnPast 12 months | +510.3% | +100.5% |
| 3-Year ReturnCumulative with dividends | +519.4% | +18.1% |
| 5-Year ReturnCumulative with dividends | +102.4% | -68.3% |
| 10-Year ReturnCumulative with dividends | -97.6% | -87.1% |
| CAGR (3Y)Annualised 3-year return | +83.7% | +5.7% |
ARMP leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ARMP and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
ARMP is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 75.3% from its 52-week high vs ARMP's 50.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARMPArmata Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.26x |
| 52-Week HighHighest price in past year | $16.34 | $26.18 |
| 52-Week LowLowest price in past year | $1.17 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +50.8% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 42.0 | 47.4 |
| Avg Volume (50D)Average daily shares traded | 50K | 252K |
Evenly matched — ARMP and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ARMP as "Buy" and DBVT as "Buy". Consensus price targets imply 134.8% upside for DBVT (target: $46) vs 80.7% for ARMP (target: $15).
| Metric | ARMPArmata Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $46.33 |
| # AnalystsCovering analysts | 4 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARMP leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallArmata Pharmaceuticals, Inc. (ARMP)Leads 2 of 6 categories
Loading custom metrics...
ARMP vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ARMP or DBVT a better buy right now?
Analysts rate Armata Pharmaceuticals, Inc.
(ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARMP or DBVT?
Over the past 5 years, Armata Pharmaceuticals, Inc.
(ARMP) delivered a total return of +102. 4%, compared to -68. 3% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: DBVT returned -87. 1% versus ARMP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARMP or DBVT?
By beta (market sensitivity over 5 years), Armata Pharmaceuticals, Inc.
(ARMP) is the lower-risk stock at 1. 24β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 1% more volatile than ARMP relative to the S&P 500.
04Which is growing faster — ARMP or DBVT?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -817. 6% for Armata Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ARMP or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -35. 4% for Armata Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -636. 7% for ARMP. At the gross margin level — before operating expenses — ARMP leads at 68. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ARMP or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ARMP or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Armata Pharmaceuticals, Inc.
(ARMP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 24)). Both have compounded well over 10 years (ARMP: -97. 6%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ARMP and DBVT?
Both stocks operate in the null sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.